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ABSTRACT
Neisseria meningitidis, a gram-negative
diplococcal bacterium, is a common
asymptomatic nasopharyngeal colonizer that
may infrequently lead to invasive disease in
the form of meningitis or bacteremia. Six
serogroups (A, B, C, W, X and Y) are
responsible for the majority of invasive
infections. Increased risk of disease occurs in
specific population groups including infants,
adolescents, those with asplenia or complement
deficiencies, and those residing in crowded
living conditions such as in college
dormitories. The incidence of invasive
meningococcal disease varies geographically
with some countries (e.g., in the African
meningitis belt) having both high endemic
disease rates and ongoing epidemics, with
annual rates reaching 1000 cases per 100,000
persons. Given the significant morbidity and
mortality associated with meningococcal
disease, it remains a major global health threat
best prevented by vaccination. Several countries
have implemented vaccination programs with
the selection of specific vaccine(s) based on
locally prevalent serogroup(s) of N. meningitidis
and targeting population groups at highest risk.
Polysaccharide meningococcal vaccines became
available over 40 years ago, but are limited by
their inability to produce immunologic
memory responses, poor immunogenicity in
infants/children, hyporesponsiveness after
repeated doses, and lack of efficacy against
nasopharyngeal carriage. In 1999, the first
meningococcal conjugate vaccines were
introduced and have been successful in
overcoming many of the shortcomings of
polysaccharide vaccines. The implementation
of meningococcal conjugate vaccination
programs in many areas of the world
(including the massive campaign in
sub-Saharan Africa using a serogroup A
conjugate vaccine) has led to dramatic
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reductions in the incidence of meningococcal
disease by both individual and population
protection. Progressive advances in
vaccinology have led to the recent licensure of
two effective vaccines against serogroup B
[MenB-4C (Bexsero) and MenB-FHbp
(Trumenba)]. Overall, the evolution of novel
meningococcal vaccines and the effective
implementation of targeted vaccination
programs has led to a substantial decrease in
the burden of disease worldwide representing a




Meningococcal disease is caused by the
gram-negative diplococcus, Neisseria
meningitidis. Although clinical descriptions of
the disease occurred in the early 1880s [1], the
first description of the organism in
cerebrospinal fluid (CSF) is attributed to
Marchiafava and Celli [2]. Three years later,
Weichselbaum identified and cultured the
organism [3].
The meningococcus, which only infects
humans, may colonize the mucosal surfaces of
the nasopharynx and upper respiratory tract.
Colonization occurs in approximately 10%
(range 3–25%) of the population with the
highest rates among adolescents and closed
populations (college students, military recruits
and multi-person households) [4]. Colonization
may last days (transient) or months (persistent),
the latter of which may serve as an immunizing
event providing protection against future
invasive infection [5–7]. Acquisition of the
bacteria from a carrier or infected person
occurs through direct contact with
large-droplet respiratory secretions, including
activities such as kissing, coughing and sharing
eating/drinking utensils.
Meningococcal disease develops after the
bacteria invades across the mucosal surface
and enters the bloodstream. Onset is typically
rapid, and fulminant disease may develop
1–14 days after acquisition [8, 9]. Clinical
syndromes include meningitis with or without
meningococcemia, the latter often manifesting
with a petechial rash or purpura fulminans [1].
N. meningitidis remains the first or second most
common cause of meningitis in many
geographic areas including the US and is the
only bacterium with the ability to produce large
meningitis outbreaks [10–12]. Other clinical
presentations of N. meningitidis infection
include pneumonia, arthritis, myocarditis,
pericarditis, urethritis and endophthalmitis [1,
9, 13, 14].
Infections frequently occur among
previously healthy persons often with
resultant high morbidity and mortality. In the
developed world, the mortality rate remains
10–15%, with rates of C20% in developing
countries [1]. Among survivors, up to 19%
have long-term sequelae including neurologic
disabilities, seizures, hearing or visual loss,
cognitive impairment, and loss of digits or
limbs [8, 9, 15, 16].
Given the ability of the meningococcus to
cause rapidly fatal and epidemic disease
worldwide, understanding preventive strategies
against this pathogen represents a global health
priority for healthcare providers, public health
personnel, and government officials worldwide.
This review article provides a summary of the
epidemiologic global trends and risk factors of
invasive meningococcal disease. Current
preventive strategies are reviewed including
the available meningococcal vaccines and
vaccination guidelines. Finally, a concise
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summary of post-exposure prophylaxis and
treatment are provided. The data within this
article are based on previously conducted
studies and do not involve any new studies of




Meningococcal disease occurs worldwide with
epidemiologic trends and causative N.
meningitidis serogroups/sequence types (ST)
varying widely by geographic location (Fig. 1)
[1, 17]. Serogroups of N. meningitidis are based
on the polysaccharide capsular structure, with
six (A, B, C, W, X and Y) of the 12 known
serogroups (A, B, C, E, H, I, K, L, W, X, Y and Z)
causing the majority of disease [1, 18–20].
Specifically, the most common ST and clonal
complexes (which are based on polymorphisms
in seven housekeeping genes) include ST-5 and
ST-7 (capsular serogroup A); ST-41/44, ST-32,
ST-18, ST-269, ST-8 and ST-35 (serogroup B);
ST-11 (serogroups C or W); ST-23 and ST-167
(serogroup Y); and ST-181 (serogroup X). Of
note, serogroup X accounts for only a small
number of invasive meningococcal disease
worldwide.
In Sub-Saharan Africa, A (ST-5 and ST-7)
historically was the predominant serogroup,
with W (ST-11), C and X (ST-181) causing
smaller numbers of cases. Since the
introduction of massive vaccination campaigns
against serogroup A, meningococcal strains
causing invasive disease have shifted towards
non-A serogroups. In the US and Canada,
serogroups B (ST-41/44, ST-32), C (ST-11) and Y
(ST-23) are the major causes of disease, and in
Europe serogroups B (ST-41/44, ST-32, ST-18,
ST-269, ST-8) and C (ST-11) predominate, the
latter showing dramatic declines after serogroup
C conjugate vaccine campaigns were introduced
[21–23]. Some European countries, such as those
Fig. 1 Map of the predominant Neisseria meningitidis serogroups by geographic location
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in Nordic Europe, also are experiencing
increasing disease from serogroup Y [24].
Further, a rapid expansion of serogroup W
cases belonging to a single clone [sequence
type 11 complex (cc11)] have recently emerged
in England and Wales [25]. Serogroup B
predominates in Australia and New Zealand
with a notable reduction in serogroup C post
introduction of meningococcal C conjugate
vaccine in Australia, whereas the incidence of
serogroup C has remained unchanged in New
Zealand with approximately 10–30 cases per
year during the past 10 years [22]. Serogroups A,
B and C predominate in Russia; and based on
limited data, serogroups A and C in Asia with
serogroup B responsible for sporadic cases in
China [17, 23]. Serogroups B and Y cause the
majority of meningococcal disease cases in
Japan, even though the incidence is very low
with an estimated \30 cases per year [17]. In
South and Latin America, B and C are most
common, with serogroup Y recently arising in
Venezuela and Columbia and the incidence of
serogroup W increasing in various countries in
the Southern Cone in Latin America, a
geographic region composed of the
southernmost regions of South America, south
of the Tropic of Capricorn, including Argentina,
Southern Brazil, Chile, Paraguay and Uruguay
[17]. In the Middle East and North Africa
serogroups include W, B, A and Y [22, 26–28].
Finally, serogroup W (cc11) has also recently
been increasingly reported in a wide diversity of
locations worldwide including South America,
South Africa and China [29–31].
An estimated [1.2 million cases and
[135,000 deaths occur annually, with
figures varying considerably given the natural
peaks and troughs of the disease that occur
every 5–12 years [22, 24, 26–28]. The
epidemiology of meningococcal disease is
determined by factors including population
characteristics (e.g., age, presence of
immunodeficiency), environmental
conditions, presence of meningococcal
serogroups that cause disease, and availability
of medical therapies (e.g., antibiotics, vaccines).
Meningococcal disease can be epidemic,
hyperendemic, or endemic (sporadic). For
example, in the African meningitis belt, which
is considered to have the highest incidence rates
in the world, many cases are linked to large
epidemics, whereas in the US, most cases (98%)
are sporadic, although outbreaks have been
reported on college campuses [32, 33]. Large
and devastating epidemics have plagued Africa
as exemplified by the 1996–1997 epidemic
resulting in [250,000 cases and [25,000
deaths [23]. While the incidence in Africa
varies over time and by geographic location,
annual rates up to 1000 cases per 100,000
population (which is 1 case per 100 persons)
have been described [14, 22]. In Europe, the
incidence is estimated as 0.92 cases per 100,000
population, while in the Americas rates range
from 0.3 to 4 cases per 100,000 population [14,
22]. An estimated 600–1200 cases occur in the
US annually with a current rate of 0.18 cases per
100,000 population [34, 35].
RISK FACTORS FOR INVASIVE
DISEASE
Since less than 1–5% of persons exposed to the
organism develop invasive disease [1], it is
known that characteristics of the organism,
host, and environment likely play a role in
disease pathogenesis. Regarding the organism,
capsular strains of N. meningitidis are more likely
to cause invasive disease as the polysaccharide
capsule serves as an important virulence factor
allowing for evasion of opsonization as well as
complement and phagocytic-mediated killing
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[36]. Further, specific genotypes of encapsulated
organisms, designated as ST clonal complexes,
vary in their virulence as shown by case:carrier
ratio studies [7, 37]. For example, serogroup W
(cc11) has been associated with both severe and
unusual presentations of the disease [25, 29].
Host factors that result in the absence of
protective bactericidal activity (due to a
deficiency in complement or antibody
production) are also risk factors for invasive
meningococcal disease. These include
functional or anatomic asplenia as well as
persistent complement deficiencies (i.e., C3,
C5–9, properdin, factor D and factor H) [38,
39]. For example, terminal complement
deficiencies (C5–9) are associated with a 1400-
to 10,000-fold increase in meningococcal
disease as well as the propensity for recurrent
infections (in up to 50% of patients) [1, 38].
Conditions with reduced complement levels
such as systemic lupus erythematous (e.g., low
C3 levels) also increase the risk. Similarly,
medications that inhibit relevant host
immune responses (e.g., eculizumab, a
humanized monoclonal antibody that inhibits
terminal complement) are risk factors [40].
Conditions associated with poor antibody
responses (e.g., congenital or acquired
antibody deficiencies such as seen in
hypogammaglobulinemia and
glomerulonephritis) also pose a risk for
invasive disease [5, 6, 41], and among these
groups, atypical presentations of invasive
disease have been described [41]. Whether
HIV-infection is a risk factor has been debated;
however, studies have shown those with AIDS
or low CD4 counts are at higher risk compared
with the general population [42]. Additionally,
outbreaks have been described among
HIV-infected men who have sex with men
(MSM) engaging in high-risk sexual behaviors
[43]. Finally, specific host genetic
polymorphisms have also been associated with
invasive disease [44–46] as well as extremes of
age (e.g.,\6 months and C65 years) [34, 47].
Environmental factors that increase
exposure to the organism include crowding
and close contact with a person carrying the
organism. For example, living in a residence
hall during the first year of college has been
associated with a higher risk of disease
compared to non-college students of similar
age groups [48]. As such, some countries (e.g.,
US) mandate education regarding
meningococcal vaccinations among
matriculating college students [49]. Other
groups that may be affected by crowding
include military recruits, with some militaries
mandating vaccination against meningococcal
disease at enlistment. Additionally,
environmental exposures may be encountered
by specific occupations such as microbiologists
[50]; healthcare personnel in general are not felt
to be at higher risk unless exposed to a patient
with meningococcal disease [49]. Other
environmental risks include residence or travel
to hyperendemic areas (e.g., the meningitis belt
in Africa) as well as pilgrimages to the Hajj in
Mecca [51, 52]. Finally, antecedent respiratory
infections (e.g., Mycoplasma, influenza and
other viruses), exposure to active or passive
smoking, and dry or windy air conditions are
associated with a heightened risk for invasive
disease due to mucosal damage and/or irritation
[53–55].
An example of the culmination of multiple
risk factors that previously led to extremely
high incidence rates was seen in the African
meningitis belt, stretching from Senegal in the
west to Ethiopia in the east. During the dry
season (December–June), dusty winds, cold
nights and upper respiratory tract infections
combined to damage the nasopharyngeal
mucosa [55, 56]. Additionally, overcrowding,
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exposures during migration and congregating at
traditional markets, and underlying medical
conditions enhanced the risk for disease. The
combination of these factors and the presence
of encapsulated, virulent serogroups of N.
meningitidis explained the previous enormous
burden of meningococcal disease observed in





While N. meningitidis remains a formidable
pathogen, tremendous strides toward its
control have been made, including the
development of effective vaccines, which first
became available [40 years ago [57, 58].
Advances in the immunogenicity and breadth
of serogroup coverage of the vaccines have
readily expanded over time [59].
Available Vaccines
Both polysaccharide and conjugated
polysaccharide meningococcal vaccines are
currently available (Table 1). Polysaccharide
vaccines include bivalent (groups A and C),
trivalent (groups A, C and W) or quadrivalent
(groups A, C, Y and W) forms. While initially
vaccines were polysaccharide in nature, newer
conjugate vaccines in which proteins are
conjugated to polysaccharide antigens have
been developed and available since the late
1990s. Polysaccharide vaccines are T
cell-independent and rely on humoral
responses; hence, the immune protection may
be short-lived. In contrast, conjugate vaccines
generate T-cell-dependent antigen-recruitment
responses. Advantages of conjugate vaccines
include their ability to elicit immunologic
memory; reduction in nasopharyngeal carriage
and hence interruption of transmission and
establishment of population protection; and
effectiveness in protecting young children
(\24 months) who may respond poorly to
conventional polysaccharide vaccines. Available
meningococcal conjugate vaccines include
monovalent (A or C), quadrivalent (A, C, Y and
W) and combination (serogroup C or C and Y,
along with Haemophilus influenzae b) vaccines.
No vaccine currently exists against serogroup X;
however, candidate glycoconjugate vaccines are
in development against this serogroup [60].
The development of an effective vaccine
against serogroup B has been challenging,
especially given the serogroup B
polysaccharide resembles a human neural cell
adhesion molecule, raising concern about
autoimmunity [61]. Initially serogroup B
vaccines were developed based on outer
membrane vesicles (OMV) that contain
proteins. OMV vaccines have been utilized in
many areas (e.g., Cuba, South America, Norway
and New Zealand) with demonstrated
protective capacities against serogroup B. For
example, the MeNZB, utilized in New Zealand,
was effective in reducing rates of disease and
controlling a serogroup B epidemic [62]. The
main limitation of these vaccines is their lack of
broad protection against the wide global
diversity of varying serogroup B strains.
Hence, improved vaccines against serogroup
B were pursued with the subsequent recent
breakthroughs using ‘‘reverse vaccinology,’’
which successfully created serogroup B
meningococcal vaccines based on conserved
proteins [63, 64]. The advantages of these new
serogroup B vaccines are several fold, including
their broad coverage, which may protect even
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Table 1 Meningococcal vaccines by geographic location
Type of vaccine Serogroup(s)
covered







3 months–29 years Meningitis vaccine project:
1–29 years





Registered for use at
C2 months, but 1st
dose can be given as
early as 6 weeks
\2 years (3 doses if initiation at
6 weeks–5 months; 2 doses if
initiation at 6–11 or
C12 months)





C8 weeks 12 months
MCC-CRM
(Meningitec)
C6 weeks 12 months
MCC-CRM
(Menjugate)





C6 weeks 12 months
Quadrivalent
conjugate
A, C, W, Y MenACWY-D
(Menactra)
2–55 years* Not routinely recommended.
Recommended in those with






1–55 years* Not routinely recommended.
Recommended in those with




A, C, W, Y MPSV4
(Menomune)
C2 years Not routinely recommended. Can
be administered when repeat
dosing not anticipated
Mencevax ACWY C2 years Not routinely recommended. Can
be administered when repeat
dosing not anticipated
Canada




2 months–17 years Not routinely administered.
High-risk individuals
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Table 1 continued
Type of vaccine Serogroup(s)
covered





C2 months 12 months, 12 years**
MCC-CRM
(Meningitec)
C2 months 12 months, 12 years**
MCC-CRM
(Menjugate)
C2 months 12 months, 12 years**
Quadrivalent
conjugate
A, C, W, Y MenACWY-D
(Menactra)
9 months–55 years* 12 years**
MenACWY-CRM
(Menveo)
2 months–55 years* 12 years**
ACWY-TT
(Nimenrix)
12 months–55 years* 12 years**
Quadrivalent
polysaccharide
A, C, W, Y MPSV4
(Menomune)
C2 years Not routinely recommended. Can










C2 months 3 months
MCC-CRM
(Menjugate)
C2 months 3 months
MCC-CRM
(Meningitec)






C2 months–2 years 12–13 months
Quadrivalent
conjugate
A, C, W, Y ACWY-CRM
(Menveo)
C2 years 14 years
ACWY-TT
(Nimenrix)
C12 months 14 years
Quadrivalent
polysaccharide
A, C, W, Y MenACWY
(ACWY Vax)
[2 years Not part of routine immunization.
Only offered for short-term
travel protection in older
children and adults
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against some non-serogroup B strains; of note,
however, these vaccines may miss some
serogroup B meningococcal strains.
Recombinant protein vaccines against
serogroup B include MenB-4C (Bexsero) and
MenB-FHbp (Trumenba); both are approved for
use in the US, with the former vaccine also
approved in Europe, Canada and Australia. Of
note, the OMV vaccine, MeNZB, contains
P1.4, a major component of the current
MenB-4C vaccine. Current serogroup B
vaccines require multiple doses with MenB-4C
given as a two-dose (0 and C1 month) and
MenB-FHbp as a three-dose (0, 2 and 6 months)
initial series; the same serogroup B vaccine
should be utilized for all doses. Quadrivalent
and serogroup B vaccines can be administered
during the same visit, but should be given at
different sites.
Vaccine Recommendations
Meningococcal vaccination is recommended for
persons at increased risk for disease. A summary
of vaccine recommendations is shown in
Table 2 [65–70].
WHO Guidance for High-Risk Countries
Populations significantly affected by
meningococcal disease should be prioritized
for vaccination with the choice of vaccine
dependent on locally prevalent N. meningitidis
serogroups. The World Health Organization
(WHO) recommends that countries with high
([10 cases per 100,000) or intermediate (2–10
cases per 100,000) endemicity conduct
large-scale meningococcal vaccine programs.
Additionally, countries with frequent
Table 1 continued
Type of vaccine Serogroup(s)
covered




10–25 years Not part of routine vaccination,
but may be given at 16–18 years
MenB-FHbp
(Trumenba)
10–25 years Not part of routine vaccination,







6 weeks–18 months Not part of routine vaccination
Quadrivalent
conjugate
A, C, W, Y MenACWY-D
(Menactra)
9 months–55 years* Single dose at 11–12 years, with
booster at 16 years
MenACWY-CRM
( Menveo)
2 months–55 years* Single dose at 11–12 years, with
booster at 16 years
Quadrivalent
polysaccharide
A, C, W, Y MPSV4
(Menomune)
C2 years Not routinely recommended. Can
be administered when repeat
dosing not anticipated
* Guidelines suggest these vaccines can be used among[55 year olds with preference for a conjugate vaccine if more than
one meningococcal dose is anticipated
** Either monovalent meningococcal C vaccine or quadrivalent meningococcal conjugate vaccine given at 12 years
(depending on local epidemiology and programmatic considerations)
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Table 2 Summary of meningococcal vaccination recommendations
Countries with high (>10 cases per 100,000) or 
intermediate (2-10 cases per 100,000) endemic 
disease 
Large scale meningococcal vaccine programs 
Countries with frequent epidemics of invasive 
disease
Large scale meningococcal vaccine programs
Countries with low (<2 cases per 100,000) endemic disease
Age/Population Group Vaccine
Australian Guidelines
12 months MenCCV or Hib/MenCCV




Students living in residential accommodations
“At risk” groups:
Functional or anatomical aspleniaa
Complement component disordersa,b 
HIV infection (regardless of CD4 count or stage of 
disease)a
Hematopoietic stem cell transplanta
Specific occupations (e.g., microbiologists, military 
recruits)
NOTE: 4vMenCV revaccination every 5 years if risk 
remains. 4vMenCV brand and doses required depends 
on age at which vaccine is initiated
MenBV & 4vMenCV
“At risk” groups (continued):
Travelers visiting areas with high endemic rates or
ongoing epidemics
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
4vMenCV. 
4vMenPV is suitable 
when repeated doses is not anticipated and 
if aged ≥ 7 years
During an outbreak Type of vaccine (MenBV, MenCCV, 
4vMenCV) based on serogroup causing 
outbreak
Canadian Guidelines
12 months MenCCV (may begin earlier, depending 
on provincial and territorial schedules)
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Table 2 continued
12 years 4vMenCV or MenCCV (depending on 
local epidemiology and programmatic 
considerations) and MenBV considered on 
an individual basis, depending on 
preferences of vaccine recipient, regional 
serogroup B disease incidence and strain 
susceptibility to MenBV vaccine
“At risk” groups:
Functional or anatomical aspleniaa
Complement component disordersa,b 
HIV infectiona
Hematopoietic stem cell transplanta
Specific occupations 
(e.g., microbiologists, military recruits)
NOTE: 4vMenCV revaccination every 5 years if risk 
remains. 4vMenCV brand and doses required depends 
on age at which vaccine is initiated
MenBV & 4vMenCV
“At risk” groups (continued):
Travelers visiting areas with high endemic rates or 
ongoing epidemics
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
4vMenCV (travelers do not need to 
receive MenBV unless travelling to area 
with an outbreak known to be caused by 
meningococcal serogroup B)
During an outbreak Type of vaccine (MenBV, MenCCV, 






12-13 months Hib/MenCCV and MenBV
14 years 4vMenCV




Functional or anatomical aspleniaa
Complement component disordersa,b 
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
MenBV, 4vMenCV, & Hib/MenCCV 
4vMenCV is given 1 month after 
Hib/MenCV if ≥ 11 years and 2 
months after if < 11 years
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Table 2 continued
“At risk” groups (continued)
HIV infectiona (<25 years who have not been 
previously vaccinated, uncertain vaccination history, 
or received last MenCCV at <10 years).
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
4vMenCV and possibly MenB
“At risk” groups (continued)
Specific occupations (e.g., microbiologists)
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
4vMenCV only included, no update on 
MenBV
“At risk” groups (continued):
Travelers visiting areas with high endemic rates or 
ongoing epidemics
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
4vMenCV only
During an outbreak Type of vaccine: (MenBV, MenCCV, 





16-18 years May consider MenBV
College students living in dormitories/residence halls who 4vMenCV
have not received a dose on or after their 16th birthday
Military recruits 4vMenCV
“At risk” groups:
Functional or anatomical aspleniaa
Complement component disordersa,b 
Specific occupations (e.g., microbiologists)
NOTE: 4vMenCV revaccination every 5 years if risk 
remains 
MenBV & 4vMenCV 
“At risk” groups (continued):
Travelers visiting areas with high endemic rates or 
ongoing epidemics
NOTE: 4vMenCV revaccination every 5 years if risk 
remains
4vMenCV 
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epidemics of invasive disease should also
initiate vaccination programs. Mass
vaccination campaigns should consider
immunizing young persons (e.g., 9 months to
18 years of age), with a preference for the use of
a conjugate vaccine given its potential for
population protection [14]. Reduced carriage
rates and population protection have been
demonstrated after conjugate vaccine
campaigns in both the UK and Africa [71–73].
Surveillance of disease rates and serogroups are
advocated after such campaigns to evaluate the
need for repeat vaccine campaigns and use
within the routine immunization programs.
An example of mass vaccination campaigns
against meningococcal disease in hyperendemic
areas is the recent efforts in the African
‘‘meningitis belt’’ countries. Following the
1996–1997 epidemic in Africa, leaders
advocated for the development and
administration of a vaccine that would
eliminate group A meningococcal epidemics.
In response, the Meningitis Vaccine Project
rolled out a MenA conjugate vaccine
(MenAfriVac) in 2010 targeting ages
1–29 years. The vaccine was priced at 50 cents
a dose (produced at the Serum Institute of India,
Ltd.) and has the advantage of a
controlled-temperature chain, allowing it to be
kept in a broader range of temperatures, a key
feature for its use in Africa. Thus far, [217
million people in 17 African countries have
received the vaccine, and surveillance data have
demonstrated dramatic reductions in
meningococcal A epidemics and carriage rates
[74]. Two formulations of MenAfriVac are
available: the 10 lg formulation used as a
single injection for 1–29 year olds and a lower
dose vaccine (5 lg) approved for ages
3–24 months [73]. The WHO recommends that
countries having completed mass vaccination
campaigns introduce the vaccine into routine
childhood immunization programs within
1–5 years (i.e., routine childhood vaccination
using the 5 lg dose administered as a single
dose at 9 months of age). A one-time ‘‘catch-up’’
campaign of vaccinating birth cohorts born
since the initial vaccine campaign is also
advised. Recommendations for further booster
doses later in life have not yet been established.
Table 2 continued
During an outbreak Type of vaccine (MenBV, 4vMenCV) 
based on serogroup causing outbreak
Consider for emerging risk groups (e.g., HIV+ MSM 
persons in New York Statea):
4vMenCV
Other Countries: Recommendations vary by country; see specific national guidelines
Adapted from Speciﬁc National Guidelines [65–70]
Hib/MenCCV H. inﬂuenzae b/monovalent meningococcal C conjugate vaccine, MenBV meningococcal B vaccine,
MenCCV monovalent meningococcal C conjugate vaccine, 4vMenCV quadrivalent meningococcal conjugate vaccine,
4vMenPV quadrivalent meningococcal polysaccharide vaccine
a 2-dose initial vaccine series recommended
b Included deﬁciencies: C3, C5–9, properdin, factor D, and factor H. In addition, the use of medications that inhibit any of
these components, such as eculizumab
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Monitoring trends and serogroups over time is
recommended to determine whether updates in
the vaccine schedule or serogroup coverage may
be needed.
Guidelines for Lower-Risk Countries
Meningococcal vaccination decisions in areas of
low incidence (\2 cases per 100,000) are more
challenging. While low incidence rates of disease
are typically seen in the developed world,
invasive disease does occur and is often
associated with high mortality rates and
substantial disability among survivors [15, 16,
49]. Guidelines regarding meningococcal
vaccination in countries with overall low
disease rates and without frequent epidemics is
variable, but most (e.g., US, Europe) recommend
vaccination for defined ‘‘at-risk’’ groups based on
age, underlying host factors, and anticipated
occupational and or travel-related exposures.
US Guidelines
In the US, meningococcal vaccination is guided
by the Advisory Committee on Immunization
Practices (ACIP) with available vaccines shown
in Table 1 [49]. Since 2005, vaccination with a
quadrivalent vaccine (MenACWY-D or
MenACWY-CRM) has been recommended for
adolescents aged 11-12 years, with
revaccination at 16 years to ensure continued
protection through the young adult years.
Vaccination is also recommended for first-year
college students living in dormitories/residence
halls who have not received a dose on or after
their 16th birthday (Table 2) [49]. Although
infants (\6 months of age) have a higher risk of
infection, routine vaccination is not
recommended in the US given the overall low
burden of disease, poor cost-effectiveness, and
since the required number of doses is not
practical over this short time frame [49, 75].
Infants and children with additional risk factors
for disease, as discussed below, are candidates
for vaccination.
For age groups outside the adolescent/young
adult years, targeted vaccination is
recommended based on the presence of
specific additional risk factors including
functional or anatomic asplenia, persistent
complement component deficiencies, and
occupations associated with exposure to the
organism (e.g., microbiologists, military
recruits) [49]. US guidelines do not include
HIV infection as an indication for vaccination
[65], although specific states (e.g., New York)
have encouraged its use in this population.
Finally, vaccine administration should be
considered in outbreak settings and directed
against the causative serogroup.
Travelers visiting areas with high endemic
rates or ongoing epidemics should be
vaccinated with a dose received at least within
the 5 years prior to travel [65]. For travelers to
the African meningitis belt, the risk is highest
during the dry season and with anticipated
contact with the local population [14].
Vaccination is required within the last 3 years
for travelers to the Hajj (given outbreaks of A, C
and W disease), a requirement of the
government of Saudi Arabia [76, 77]. Vaccines
should be directed against the serogroups that
are prevalent in the visited areas and should be
given at least 10 days prior to departure to
ensure protective antibody levels. For example,
the quadrivalent conjugate vaccines (A, C, W
and Y) should cover the most prevalent strains
currently in the African meningitis belt and
Saudi Arabia. A conjugate vaccine is preferred
among travelers, especially among those who
take repeated trips to endemic areas. This latter
recommendation is based on data suggesting
that receipt of two polysaccharide vaccinations
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may result in immune hyporesponsiveness,
whereas repeated conjugate vaccines may
boost antibody levels [49, 78, 79].
Vaccination in the US is typically with a
quadrivalent vaccine that covers serogroups A,
C, W and Y. Both conjugate [MenACWY-D
(Menactra), MenACWY-CRM (Menveo)] and
polysaccharide [MPSV4 (Menomune)]
quadrivalent vaccines are available and
licensed for specific age groups (Table 1) [49].
A bivalent conjugate meningococcal vaccine is
available in the US [HibMenCY-TT (MenHibrix)]
and also offers coverage against Haemophilus
influenzae b, but only contains two
meningococcal serogroups (C, Y). In general,
conjugate vaccines are preferred; however,
polysaccharide vaccines can be used when the
conjugate vaccine is unavailable and for those
C56 years who require only a single vaccine
dose [65].
Since serogroup B now accounts for 40% of
the cases in the US [47], vaccination with
MenB-4C or MenB-FHbp has been added to
the immunization schedule for those at highest
risk including persons with asplenia, persistent
complement component deficiencies, and
occupations such as microbiologists [64].
Serogroup B vaccination can also be
considered among other at-risk groups (e.g.,
adolescents, college students); however, it is not
currently uniformly recommended given the
overall low burden of disease. For example, if
the vaccine were administered in the US at ages
11 and 16–18 years, an estimated 15–29 cases
and 2–5 deaths might be prevented each year; if
given only to college students, an estimated
nine cases and one death might be averted each
year [80]. If the serogroup B vaccine is utilized,
the preferred strategy per ACIP guidelines is to
administer it later in adolescence (i.e., aged
16–18 years) to maximize protection during the
highest age risk period [80]. Overall, individual
clinical decision making has been advised
regarding the use of the serogroup B vaccine
among US adolescents and young adults who
do not have additional risk factors.
Additionally, in the setting of increased
serogroup B cases or outbreaks (defined as C2
primary cases in organizations with \5000
persons over a 6 month period), vaccination is
advised [64, 65, 81].
European Guidelines
The use of meningococcal vaccination in
Europe differs from the US given the
geographically varying epidemiologic trends.
In 1999, the MenC conjugate vaccine was
added to the UK’s routine immunization
schedule, resulting in significant and sustained
reductions in serogroup C cases [22, 68]. In
2013, the serogroup B vaccine, MenB-4C, was
approved for persons C2 months of age and
subsequently added to the vaccine schedule
[82]. Current UK guidelines suggest the
administration of two doses of serogroup B at
2 and 4 months followed by a booster at
12–13 months of age and one dose of
serogroup C meningococcal conjugate vaccine
at 3 months of age [MCC-TT (Neisvac-C) or
MCC-CRM (Menjugate)], followed by an
MCC-TT/Hib-TT (MenC/H. influenzae type b
conjugate) vaccine at 12–13 months [68,
83–85].
The recent expansion of the hyper-virulent
serogroup W strain (cc11) led to an adolescent
MenACWY conjugate vaccination program
initiated in 2015 for those 14 years of age [86].
Hence, a quadrivalent meningococcal
conjugate (ACWY-CRM or ACWY-TT) is
administered among these age groups. For
those entering university with an unknown
immunization history, a conjugate
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quadrivalent ACWY vaccine dose is also
recommended (Table 2).
In addition, those at risk for disease (e.g.,
asplenia, complement disorders) should receive
vaccination based on the age at which their risk
condition is diagnosed [68]. The UK guidelines
also recommend a dose of conjugate MenACWY
for those traveling to hyperendemic or
epidemic areas, even if previously vaccinated
with MenC [68]. Finally, the British HIV
Association suggests vaccination among
HIV-infected persons aged\25 years [69].
Other European countries have also
introduced meningococcal C vaccinations into
their immunization programs, some as part of
the infant immunization schedule (e.g., Greece,
Iceland, Ireland, Portugal, Spain and the UK),
while others advise initiation during the 2nd
year of life (e.g., Belgium, Cyprus, Italy and The
Netherlands) [22, 85]. The European
Commission approved MenB-4C in 2013, and
the UK subsequently was the first country to
introduce MenB-4C into their national infant
immunization program (2015). As noted above,
most countries also recommend vaccination
among those at high risk for disease (e.g.,
asplenia, terminal complement deficiencies)
and travelers to endemic areas with some
variations by country. A summary of European
recommendations by country can be found on
the European Centre for Disease Prevention and
Control website [85].
Guidelines for Other Locations
Country-specific guidelines have been
developed for other regions of the world [22,
87]. Guidance for Australia and Canada are
shown in Table 2 [66, 70]. Overall, vaccine
strategies against meningococcal disease vary
worldwide and should be based on local
epidemiologic trends derived from ongoing
surveillance data. Since Neisseria are capable of
undergoing capsular switching (e.g., ST11,
which is typically associated with serogroup C,
can alter its capsule to serogroup B) [88] and
serogroup/ST replacement can occur over time,
continued reassessment of trends and
serogroups is advocated to ensure optimal
vaccine programs. The importance of
surveillance in serogroup trends is exemplified
by the global spread of serogroup W (cc11)
causing severe cases of invasive disease [29, 31].
Number of Vaccinations
Establishment of protection against invasive
disease is via the development of serum
bactericidal antibodies against N. meningitidis
capsular polysaccharides or protein antigens.
Due to the low incidence of meningococcal
disease in much of the world, vaccine
effectiveness has largely been based on
immunogenicity data as measured by serum
bactericidal activity (SBA) [14].
The number of vaccines utilized in the initial
series is based on host characteristics including
age and underlying medical conditions. In most
adults and children (age C24 months), a single
dose is recommended for initial vaccination.
Additional doses are generally recommended
among infants and toddlers B23 months [68,
89]. Furthermore, among children and adults
with underlying medical conditions [e.g.,
asplenia, persistent complement component
deficiencies and immunosuppression (e.g.,
HIV)], significantly lower antibody titers have
been achieved after a single dose [90, 91].
Hence, when these groups are vaccinated,
additional vaccine doses are often
recommended [65–70]. For example, in the US,
these groups receive a two-dose initial series
administered 8–12 weeks apart [49, 65].
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Current vaccines do not provide lifelong
protection even though the risk for
meningococcal disease persists among all ages.
In general, polysaccharide vaccines induce
3–5 years of protection among adults.
Although it was hoped that conjugate vaccines
would induce immune responses with longer
durations of protection, this may not be the
case after single dose administration [47]. For
example, among adolescents, one study
demonstrated vaccine effectiveness for
MenACWY at 1 year post-vaccination of 82%,
but found waning protection (50–60%) at
2–5 years [49]. The durability of protection of
the broad-spectrum, protein serogroup B
vaccines (MenB-4C and MenB-FHbp) remains
unknown. Therefore, some guidelines
recommend booster doses among those who
remain at high risk for the disease. For example,
in countries such as Australia, Canada, the UK
and US, a booster dose of conjugate quadrivalent
ACWY vaccine is recommended every 5 years for
persons at continued high risk such as
microbiologists, patients with asplenia or
persistent complement component
deficiencies, immunosuppressed (HIV) patients,
and frequent travelers to endemic areas [65–70].
Among children at higher risk for disease,
revaccination is recommended 3 years after the
initial dose if received at an ageB6 years [49, 92].
Vaccine Administration
Most polysaccharide vaccines are administered
by subcutaneous injection, whereas conjugate
vaccines are given by intramuscular injection,
typically in the deltoid muscle, except among
those \12 months, in whom the anterolateral
thigh is preferred [14].
Co-administration of the meningococcal
vaccine with other routinely administered
vaccines appears to be generally safe and
without significant effect on vaccine efficacy;
administration should use separate injection
sites [65, 74, 83, 84, 93]. For example, studies of
MenAfriVac suggest that it can be administered
at the same visit as routine vaccines (e.g.,
diphtheria, tetanus toxoid, whole cell
pertussis, hepatitis B, measles, rubella, oral
poliovirus, H. influenzae b and yellow fever);
the conjugate pneumococcal vaccine (Prevnar)
and rotavirus vaccines were not evaluated [74].
Studies on the conjugate quadrivalent
meningococcal vaccine (MenACWY-D,
Menactra) with PCV13 (Prevnar) did find
reduced antibody titers to some pneumococcal
serogroups, but levels were still in the protective
range [94]. Due to the high risk of invasive
pneumococcal disease in children with
functional or anatomic asplenia, the Centers
for Disease Control and Prevention (CDC) in
the US recommend considering administration
of MenACWY-D at least 4 weeks after
completion of all PCV13 doses [95]. Finally,
although some meningococcal conjugate
vaccines (i.e., MenACWY-D and
MenACWY-CRM) contain diphtheria toxoid,
no adverse findings have been noted with




Millions of doses of polysaccharide and, more
recently, conjugate vaccines have been
administered worldwide, demonstrating an
excellent safety profile to date. Adverse
reactions when they do occur are typically
mild and most commonly are injection site
erythema or tenderness [97]. Post-vaccination
headache, fever or dizziness may occur. Syncope
has been reported especially among
adolescents. While Guillian-Barre syndrome
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has been reported, the risk does not appear to be
elevated based on US data evaluating the
meningococcal conjugate MenACWY-D
(Menactra) vaccine or Canadian data on
MCC-CRM (Menjugate) [98, 99]. Allergic
reactions and/or anaphylaxis are uncommon
(e.g., estimated as\0.1/100,000 vaccines doses
for polysaccharide vaccines) [14].
Use in Pregnancy
Although meningococcal vaccines have not
been extensively studied in pregnancy or
lactating women and no randomized trials are
available, an observational study of the
MenAfriVac did not show any adverse signals
for pregnancy outcomes. As such, pregnant
women in the targeted age range are being
included in the mass vaccine campaigns in
Africa [74]. Similarly, the Vaccine Adverse Event
Reporting System (VAERS) system in the US has
identified no major safety concerns in the
mother or fetus [49, 100]. Hence, based on the
available data, pregnancy or lactation is not





Close contacts of patients with invasive disease
have a markedly increased risk for developing
meningococcal infection (estimated as
[100-fold increase compared with the general
population) [49, 102]. As such, prophylactic
antibiotics are recommended for close contacts
including household members or persons in the
same daycare, college dormitory or military unit
[49, 92]. Additionally, those directly exposed to
a patient’s oral secretions (kissing, sharing food
or drink utensils, or mouth-to-mouth
resuscitation) within the 7 days before
symptom onset should be offered prophylaxis
[49].
Secondary cases most often occur within
72 h of presentation of the index cases; hence,
antibiotic prophylaxis should be initiated
immediately, ideally within 24 h of the
identification of the index case. Presentation
may occur up to 14 days of exposure; hence,
prophylaxis can be offered up to this time point
[49]. Chemoprophylaxis in the setting of
ongoing epidemics and exposures (e.g., the
African meningitis belt) are often not pursued
given the multiple sources and prolonged risk of
exposures; vaccine protection is the best
preventive strategy in these settings.
Prophylactic antibiotic regimens may
include oral ciprofloxacin (adult dose:
500 mg 9 1 dose), ceftriaxone (adult dose:
250 mg IM 9 1; children \15 years: 125 mg
IM 9 1), rifampin (dose dependent on age; adult
dose: 600 mg po bid 9 2 days) or azithromycin
(10 mg/kg with maximum dose of 500 mg 9 1)
[49, 103]. Effectiveness is estimated as 90–95%
[104]. The preferred chemoprophylaxis depends
on existing resistance patterns among strains in
the geographic area of acquisition as well as
host characteristics such as age, underlying
medical conditions, pregnancy status and
concurrent medications. For example, reports
of rifampin- and ciprofloxacin-resistant N.
meningitidis isolates have been described [105,
106].
Other methods for preventing disease
include prompt diagnosis and management of
patients with invasive disease. Historically,
treatment was with immune antiserum and
then with sulfonamides during the early
antibiotic era [1, 107]. As sulfonamides are no
longer viable options due to resistance,
treatment today is typically with the
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immediate institution of intravenous
ceftriaxone or cefotaxime, with alternate
options including chloramphenicol or
meropenem [108]. Penicillin may be utilized if
the isolate is shown to be susceptible by
microbiologic testing; confirmation is advised
since 3–16% of isolates have MICs in the
intermediate susceptibility range [1, 105].
Infected patients should be maintained in
droplet precautions until at least 24 h after
treatment to prevent spread. The index case
should also receive therapy to eradicate the
carrier state if penicillin, ampicillin or
chloramphenicol was used because these
antibiotics do not reliably clear carriage; the
same regimens for eradicating carriage can be
used as for close contacts. Finally, reduction in
crowding and other risk factors discussed above
are also important for disease reduction.
CONCLUSION
N. meningitidis remains a continually evolving
disease with diverse and varying geographic
trends. Vaccines are currently available for five
of the six serogroups that cause the majority of
disease, and many countries have implemented
meningococcal vaccine programs with
subsequent reductions in the burden of
disease. Recent accomplishments include the
widespread availability of meningococcal
conjugate vaccines that cover four of the most
common serogroups (A, C, W, Y) causing
human disease, are immunogenic in infants/
children and provide population protection; the
long awaited licensure of vaccines to combat
serogroup B; and the successful mass
vaccination campaigns including in areas such
as the African meningitis belt. Future efforts
should focus on establishing robust worldwide
surveillance systems to track incidence rates
and disease-related ST complexes/serogroups in
order to inform vaccine guidelines. In addition,
the continued worldwide implementation of
vaccine initiatives to control disease is
advocated. Further, enhanced surveillance pre-
and post- introduction of vaccine interventions,
especially the complex broad-spectrum
anti-serogroup B vaccines, is essential for the
development of future control strategies against
meningococcal disease. Finally, the
development of novel vaccines with broad
serogroup coverage and long durability should
be pursued.
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